DEM1 Inhibitors
DEM1 inhibitors consist of a diverse set of chemical compounds that suppress DEM1 by targeting specific signaling pathways that are implicated in its regulation. For example, Staurosporine, a potent kinase inhibitor, disrupts protein kinase C (PKC) activity, a kinase that may be critical for DEM1 function, leading to the attenuation of DEM1's role in cellular processes. LY 294002 and Wortmannin are PI3K inhibitors that, by blocking PI3K, reduce Akt signaling and subsequently decrease DEM1 activity, given the role of PI3K/Akt pathway in regulating functions that may involve DEM1. PD 98059 and U0126 are MEK inhibitors that exert their effects on the MAPK/ERK pathway; reduction in this pathway's activity is understood to correlate with a decrease in DEM1 function. SB 203580 and SP600125, inhibitors of p38 MAPK and JNK respectively, also contribute to the suppression of DEM1 by hindering pathways that may intersect with DEM1's regulatory mechanisms.
Rapamycin, an mTOR inhibitor, impairs a central regulatory pathway, which is thought to affect DEM1 activity through downstream effects on the PI3K/Akt/mTOR signaling axis. Triciribine, by inhibiting Akt, has a similar effect in reducing the functional role of DEM1. Furthermore, the receptor tyrosine kinase inhibitors Sunitinib and Dasatinib, along with the EGFR inhibitor Erlotinib, contribute to the constellation of DEM1 inhibitors by targeting various tyrosine kinases that potentially participate in the regulation of DEM1. Each of these inhibitors, by modulating different signaling molecules and pathways, cumulatively contributes to a decrease in DEM1 activity, highlighting the complex interplay of cellular signaling in the regulation of protein function.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases, including PKC which is critical for cell signaling. Inhibition of PKC can diminish DEM1 activity by reducing phosphorylation events that are necessary for DEM1 function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a specific inhibitor of PI3K, which plays a role in the Akt signaling pathway. By blocking PI3K, LY 294002 indirectly leads to reduced phosphorylation and activation of Akt, which in turn can lead to diminished DEM1 activity as Akt can be involved in DEM1 regulation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is an inhibitor of MEK, which is part of the MAPK/ERK pathway. By inhibiting MEK, PD 98059 can reduce ERK activation and indirectly reduce DEM1 activity, as the MAPK/ERK pathway can regulate DEM1 function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a specific inhibitor of p38 MAPK. By inhibiting p38 MAPK, SB203580 can decrease DEM1 activity by affecting stress response signaling pathways that influence DEM1 function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor and by inhibiting mTOR, it can indirectly diminish DEM1 activity through the PI3K/Akt/mTOR pathway, which is associated with many cellular processes including those that might regulate DEM1. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that can diminish DEM1 activity through the PI3K/Akt pathway by preventing the necessary phosphorylation events that might be crucial for DEM1 function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are upstream regulators of the ERK pathway. By inhibiting MEK1/2, U0126 can diminish DEM1 activity by affecting the MAPK/ERK pathway that may regulate DEM1's cellular functions. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is part of the MAPK signaling pathway. By inhibiting JNK, SP600125 can lead to decreased DEM1 activity as JNK can be involved in the regulatory processes affecting DEM1. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine is an Akt inhibitor, which can lead to diminished DEM1 activity by inhibiting the phosphorylation and activation of Akt, thereby impacting signaling pathways that regulate DEM1. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib is a receptor tyrosine kinase inhibitor that can diminish DEM1 activity by inhibiting RTK signaling pathways that could be involved in the regulation of DEM1. | ||||||